EASL-EASD-EASO Clinical Practice Guidelines for the Management of Non-Alcoholic Fatty Liver Disease

[1]  J. Reinus,et al.  Extrahepatic Complications of Nonalcoholic Fatty Liver Disease. , 2016, Clinics in liver disease.

[2]  Rachel M. Brown,et al.  Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study , 2016, The Lancet.

[3]  Marcello Maida,et al.  The severity of steatosis influences liver stiffness measurement in patients with nonalcoholic fatty liver disease , 2015, Hepatology.

[4]  Marco Maggioni,et al.  Statin use and non-alcoholic steatohepatitis in at risk individuals. , 2015, Journal of hepatology.

[5]  S. Friedman,et al.  Weight Loss Through Lifestyle Modification Significantly Reduces Features of Nonalcoholic Steatohepatitis. , 2015, Gastroenterology.

[6]  F. Pattou,et al.  Bariatric Surgery Reduces Features of Nonalcoholic Steatohepatitis in Morbidly Obese Patients. , 2015, Gastroenterology.

[7]  Asociacion Latinoamericana para el Estudio del Higado.  EASL-ALEH Clinical Practice Guidelines: Non-invasive tests for evaluation of liver disease severity and prognosis. , 2015, Journal of hepatology.

[8]  M. Carstensen,et al.  Adaptation of hepatic mitochondrial function in humans with non-alcoholic fatty liver is lost in steatohepatitis. , 2015, Cell metabolism.

[9]  A. Burt,et al.  Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: implications for prognosis and clinical management. , 2015, Journal of hepatology.

[10]  E. Bugianesi,et al.  The combination of liver stiffness measurement and NAFLD fibrosis score improves the noninvasive diagnostic accuracy for severe liver fibrosis in patients with nonalcoholic fatty liver disease , 2015, Liver international : official journal of the International Association for the Study of the Liver.

[11]  Mats Fredrikson,et al.  Fibrosis stage is the strongest predictor for disease‐specific mortality in NAFLD after up to 33 years of follow‐up , 2015, Hepatology.

[12]  B. Neuschwander‐Tetri,et al.  Clinical Model for NASH and Advanced Fibrosis in Adult Patients With Diabetes and NAFLD: Guidelines for Referral in NAFLD , 2015, Diabetes Care.

[13]  Z. Goodman,et al.  Current efforts and trends in the treatment of NASH. , 2015, Journal of hepatology.

[14]  Zhen Wang,et al.  Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies. , 2015, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[15]  S. Friedman,et al.  Challenges and opportunities in drug and biomarker development for nonalcoholic steatohepatitis: Findings and recommendations from an American Association for the Study of Liver Diseases–U.S. Food and Drug Administration Joint Workshop , 2015, Hepatology.

[16]  B. Neuschwander‐Tetri,et al.  Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial , 2015, The Lancet.

[17]  Aijaz Ahmed,et al.  Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States. , 2015, Gastroenterology.

[18]  M. Orho-Melander,et al.  Circulating triacylglycerol signatures and insulin sensitivity in NAFLD associated with the E167K variant in TM6SF2. , 2015, Journal of hepatology.

[19]  H. El‐Serag,et al.  Temporal trends of nonalcoholic fatty liver disease-related hepatocellular carcinoma in the veteran affairs population. , 2015, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[20]  D. Brenner,et al.  Ezetimibe for the Treatment of Nonalcoholic Steatohepatitis: Assessment by Novel Magnetic Resonance Imaging and Magnetic Resonance Elastography in a Randomized Trial (MOZART Trial) , 2015, Hepatology.

[21]  N. Lundbom,et al.  Liver fat content and hepatic insulin sensitivity in overweight patients with type 1 diabetes. , 2015, The Journal of clinical endocrinology and metabolism.

[22]  J. Borén,et al.  Transmembrane 6 superfamily member 2 gene variant disentangles nonalcoholic steatohepatitis from cardiovascular disease , 2015, Hepatology.

[23]  J. Everhart,et al.  Fatty liver indices in the multiethnic United States National Health and Nutrition Examination Survey , 2015, Alimentary pharmacology & therapeutics.

[24]  S. Burks,et al.  Effects of n-3 fish oil on metabolic and histological parameters in NASH: a double-blind, randomized, placebo-controlled trial. , 2015, Journal of hepatology.

[25]  G. Marchesini,et al.  NAFLD incidence and remission: only a matter of weight gain and weight loss? , 2015, Journal of hepatology.

[26]  B. Neuschwander‐Tetri,et al.  Relationship between changes in serum levels of keratin 18 and changes in liver histology in children and adults with nonalcoholic fatty liver disease. , 2014, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[27]  S. Hunt,et al.  A single non‐invasive model to diagnose non‐alcoholic fatty liver disease (NAFLD) and non‐alcoholic steatohepatitis (NASH) , 2014, Journal of gastroenterology and hepatology.

[28]  Jimmy D Bell,et al.  External validation of the fatty liver index and lipid accumulation product indices, using 1H-magnetic resonance spectroscopy, to identify hepatic steatosis in healthy controls and obese, insulin-resistant individuals. , 2014, European journal of endocrinology.

[29]  F. Nascimbeni,et al.  Performance and limitations of steatosis biomarkers in patients with nonalcoholic fatty liver disease , 2014, Alimentary pharmacology & therapeutics.

[30]  H. Yki-Järvinen.  Non-alcoholic fatty liver disease as a cause and a consequence of metabolic syndrome. , 2014, The lancet. Diabetes & endocrinology.

[31]  F. Pattou,et al.  Roux-en-Y Gastric Bypass Versus Adjustable Gastric Banding to Reduce Nonalcoholic Fatty Liver Disease: A 5-Year Controlled Longitudinal Study , 2014, Annals of surgery.

[32]  J. Lavine,et al.  Review article: the management of paediatric nonalcoholic fatty liver disease , 2014, Alimentary pharmacology & therapeutics.

[33]  Y. Ngo,et al.  Prognostic value of liver fibrosis and steatosis biomarkers in type‐2 diabetes and dyslipidaemia , 2014, Alimentary pharmacology & therapeutics.

[34]  J. Jónasson,et al.  Long term follow-up and liver-related death rate in patients with non-alcoholic and alcoholic related fatty liver disease , 2014, BMC Gastroenterology.

[35]  G. Frühbeck,et al.  Increased Cardiometabolic Risk Factors and Inflammation in Adipose Tissue in Obese Subjects Classified as Metabolically Healthy , 2014, Diabetes Care.

[36]  O. Cummings,et al.  No significant effects of ethyl-eicosapentanoic acid on histologic features of nonalcoholic steatohepatitis in a phase 2 trial. , 2014, Gastroenterology.

[37]  P. Bedossa.  Utility and appropriateness of the fatty liver inhibition of progression (FLIP) algorithm and steatosis, activity, and fibrosis (SAF) score in the evaluation of biopsies of nonalcoholic fatty liver disease , 2014, Hepatology.

[38]  E. Gaudio,et al.  Nonalcoholic fatty liver disease and the heart in children and adolescents. , 2014, World journal of gastroenterology.

[39]  Z. Halpern,et al.  Non‐high‐density lipoprotein cholesterol independently predicts new onset of non‐alcoholic fatty liver disease , 2014, Liver international : official journal of the International Association for the Study of the Liver.

[40]  J. Dufour,et al.  Carriage of the PNPLA3 rs738409 C >G polymorphism confers an increased risk of non-alcoholic fatty liver disease associated hepatocellular carcinoma. , 2014, Journal of hepatology.

[41]  H. Völzke,et al.  Association of Non-alcoholic Fatty Liver Disease with Chronic Kidney Disease: A Systematic Review and Meta-analysis , 2014, PLoS medicine.

[42]  K. Clément,et al.  TM6SF2 rs58542926 influences hepatic fibrosis progression in patients with non-alcoholic fatty liver disease , 2014, Nature Communications.

[43]  N. Hayashi,et al.  Clinical characteristics, treatment, and prognosis of non-B, non-C hepatocellular carcinoma: a large retrospective multicenter cohort study , 2014, Journal of Gastroenterology.

[44]  Aijaz Ahmed,et al.  Nonalcoholic steatohepatitis is the most rapidly growing indication for liver transplantation in patients with hepatocellular carcinoma in the U.S. , 2014, Hepatology.

[45]  Aijaz Ahmed,et al.  Improved survival outcomes in patients with non‐alcoholic steatohepatitis and alcoholic liver disease following liver transplantation: an analysis of 2002–2012 United Network for Organ Sharing data , 2014, Clinical transplantation.

[46]  Deepak L. Bhatt,et al.  Bariatric surgery versus intensive medical therapy for diabetes--3-year outcomes. , 2014, The New England journal of medicine.

[47]  L. N. Valenti,et al.  A 4-Polymorphism Risk Score Predicts Steatohepatitis in Children With Nonalcoholic Fatty Liver Disease , 2014, Journal of pediatric gastroenterology and nutrition.

[48]  V. de Lédinghen,et al.  Controlled attenuation parameter (CAP) for the diagnosis of steatosis: a prospective study of 5323 examinations. , 2014, Journal of hepatology.

[49]  G. Cho,et al.  Non-alcoholic fatty liver disease, metabolic syndrome and subclinical cardiovascular changes in the general population , 2014, Heart.

[50]  S. Saab,et al.  Impact of coffee on liver diseases: a systematic review , 2014, Liver international : official journal of the International Association for the Study of the Liver.

[51]  M. Orho-Melander,et al.  A population-based study on the prevalence of NASH using scores validated against liver histology. , 2014, Journal of hepatology.

[52]  L. N. Valenti,et al.  A randomized trial of iron depletion in patients with nonalcoholic fatty liver disease and hyperferritinemia. , 2014, World journal of gastroenterology.

[53]  He Zhang,et al.  Systematic evaluation of coding variation identifies a candidate causal variant in TM6SF2 influencing total cholesterol and myocardial infarction risk , 2014, Nature Genetics.

[54]  Xiaofei Wang,et al.  Outcomes of liver transplantation for nonalcoholic steatohepatitis: a systematic review and meta-analysis. , 2014, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[55]  Lawrence A Leiter,et al.  Effect of fructose on markers of non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis of controlled feeding trials , 2014, European Journal of Clinical Nutrition.

[56]  Anne Tybjærg-Hansen,et al.  Exome-wide association study identifies a TM6SF2 variant that confers susceptibility to nonalcoholic fatty liver disease , 2014, Nature Genetics.

[57]  J. George,et al.  The role of diet and nutritional intervention for the management of patients with NAFLD. , 2014, Clinics in liver disease.

[58]  M. Ngu,et al.  Systematic review with meta‐analysis: non‐invasive assessment of non‐alcoholic fatty liver disease – the role of transient elastography and plasma cytokeratin‐18 fragments , 2014, Alimentary pharmacology & therapeutics.

[59]  G. Marchesini,et al.  The role of medications for the management of patients with NAFLD. , 2014, Clinics in liver disease.

[60]  D. Lawlor,et al.  Nonalcoholic Fatty Liver Disease, Liver Fibrosis, and Cardiometabolic Risk Factors in Adolescence: A Cross-Sectional Study of 1874 General Population Adolescents , 2014, The Journal of clinical endocrinology and metabolism.

[61]  G. Hubens,et al.  Prothrombotic factors in histologically proven nonalcoholic fatty liver disease and nonalcoholic steatohepatitis , 2014, Hepatology.

[62]  L. Henry,et al.  Systematic review with meta‐analysis: non‐alcoholic steatohepatitis ‐ a case for personalised treatment based on pathogenic targets , 2014, Alimentary pharmacology & therapeutics.

[63]  H. Conjeevaram,et al.  Effect of lifetime alcohol consumption on the histological severity of non‐alcoholic fatty liver disease , 2014, Liver international : official journal of the International Association for the Study of the Liver.

[64]  S. Hazen,et al.  OxNASH Score Correlates with Histologic Features and Severity of Nonalcoholic Fatty Liver Disease , 2011, Digestive Diseases and Sciences.

[65]  K. Cusi,et al.  Limited value of plasma cytokeratin-18 as a biomarker for NASH and fibrosis in patients with non-alcoholic fatty liver disease. , 2014, Journal of hepatology.

[66]  M. Cole,et al.  Hepatocellular cancer: the impact of obesity, type 2 diabetes and a multidisciplinary team. , 2014, Journal of hepatology.

[67]  K. Clément,et al.  TM 6 SF 2 rs 58542926 Influences Hepatic Fibrosis Progression in Patients with Non-Alcoholic Fatty Liver Disease , 2014 .

[68]  M. Honda,et al.  The effects of ezetimibe on non-alcoholic fatty liver disease and glucose metabolism: a randomised controlled trial , 2014, Diabetologia.

[69]  F. Wolf,et al.  Standards of Medical Care in Diabetes—2016 Abridged for Primary Care Providers , 2016, Clinical Diabetes.

[70]  W. März,et al.  The fatty liver index is associated with increased mortality in subjects referred to coronary angiography. , 2013, Nutrition, metabolism, and cardiovascular diseases : NMCD.

[71]  Yoosoo Chang,et al.  Cohort Study of Non-alcoholic Fatty Liver Disease, NAFLD fibrosis score, and the Risk of Incident Diabetes in a Korean population , 2013, The American Journal of Gastroenterology.

[72]  E. Bjornsson,et al.  Simple noninvasive systems predict long-term outcomes of patients with nonalcoholic fatty liver disease. , 2013, Gastroenterology.

[73]  M. Al-mallah,et al.  A systematic review: burden and severity of subclinical cardiovascular disease among those with nonalcoholic fatty liver; should we care? , 2013, Atherosclerosis.

[74]  Federico Schena,et al.  Both resistance training and aerobic training reduce hepatic fat content in type 2 diabetic subjects with nonalcoholic fatty liver disease (the RAED2 randomized trial) , 2013, Hepatology.

[75]  L. Beilin,et al.  Importance of cardiometabolic risk factors in the association between nonalcoholic fatty liver disease and arterial stiffness in adolescents , 2013, Hepatology.

[76]  P. Bedossa,et al.  A systematic review of follow-up biopsies reveals disease progression in patients with non-alcoholic fatty liver. , 2013, Journal of hepatology.

[77]  S. Mudaliar,et al.  Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease. , 2013, Gastroenterology.

[78]  Ioan Sporea,et al.  Meta‐analysis: ARFI elastography versus transient elastography for the evaluation of liver fibrosis , 2013, Liver international : official journal of the International Association for the Study of the Liver.

[79]  J. Tomlinson,et al.  Non-alcoholic fatty liver disease in common endocrine disorders. , 2013, European journal of endocrinology.

[80]  Hüseyin Yilmaz,et al.  Left ventricular function by echocardiography, tissue Doppler imaging, and carotid intima-media thickness in obese adolescents with nonalcoholic fatty liver disease. , 2013, The American journal of cardiology.

[81]  Xiao-bo Yang,et al.  Fatty liver index correlates with non-alcoholic fatty liver disease, but not with newly diagnosed coronary artery atherosclerotic disease in Chinese patients , 2013, BMC Gastroenterology.

[82]  B. Neuschwander‐Tetri,et al.  Vitamin E and changes in serum alanine aminotransferase levels in patients with non‐alcoholic steatohepatitis , 2013, Alimentary pharmacology & therapeutics.

[83]  G. Ward,et al.  The Mediterranean diet improves hepatic steatosis and insulin sensitivity in individuals with non-alcoholic fatty liver disease. , 2013, Journal of hepatology.

[84]  H. Kirikoshi,et al.  Soluble CD14 Levels Reflect Liver Inflammation in Patients with Nonalcoholic Steatohepatitis , 2013, PloS one.

[85]  A. Burt,et al.  Are simple noninvasive scoring systems for fibrosis reliable in patients with NAFLD and normal ALT levels? , 2013, European journal of gastroenterology & hepatology.

[86]  G. Svegliati-Baroni,et al.  A 360-degree overview of paediatric NAFLD: recent insights. , 2013, Journal of hepatology.

[87]  G. Targher,et al.  Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis , 2013, Nature Reviews Gastroenterology &Hepatology.

[88]  H. Cortez‐Pinto,et al.  Non-invasive diagnosis of non-alcoholic fatty liver disease. A critical appraisal. , 2013, Journal of hepatology.

[89]  R. DeFronzo,et al.  Non-Alcoholic Fatty Liver Disease (NAFLD) and Its Connection with Insulin Resistance, Dyslipidemia, Atherosclerosis and Coronary Heart Disease , 2013, Nutrients.

[90]  T. Therneau,et al.  Association between noninvasive fibrosis markers and mortality among adults with nonalcoholic fatty liver disease in the United States , 2013, Hepatology.

[91]  Sombat Treeprasertsuk,et al.  NAFLD fibrosis score: a prognostic predictor for mortality and liver complications among NAFLD patients. , 2013, World journal of gastroenterology.

[92]  C. Byrne,et al.  Non-Alcoholic Fatty Liver Disease Is Associated with an Increased Incidence of Atrial Fibrillation in Patients with Type 2 Diabetes , 2013, PloS one.

[93]  Moshe Leshno,et al.  Comparison of fatty liver index with noninvasive methods for steatosis detection and quantification. , 2013, World journal of gastroenterology.

[94]  A. Feldstein,et al.  Development and validation of a new histological score for pediatric non-alcoholic fatty liver disease. , 2012, Journal of hepatology.

[95]  D. Torres,et al.  Physical activity: an essential component of lifestyle modification in NAFLD , 2012, Nature Reviews Gastroenterology &Hepatology.

[96]  V. Wong,et al.  Liver Stiffness Measurement Using XL Probe in Patients With Nonalcoholic Fatty Liver Disease , 2012, The American Journal of Gastroenterology.

[97]  F. Negro,et al.  Nonalcoholic Fatty Liver Disease in Lean Individuals in the United States , 2012, Medicine.

[98]  L. Gerber,et al.  Non‐alcoholic fatty liver disease (NAFLD) is associated with low level of physical activity: a population‐based study , 2012, Alimentary pharmacology & therapeutics.

[99]  M. Abraham,et al.  Association between diabetes, family history of diabetes, and risk of nonalcoholic steatohepatitis and fibrosis , 2012, Hepatology.

[100]  Sung-il Cho,et al.  Impact of BMI on the incidence of metabolic abnormalities in metabolically healthy men , 2012, International Journal of Obesity.

[101]  A. Sanyal,et al.  Modest alcohol consumption is associated with decreased prevalence of steatohepatitis in patients with non-alcoholic fatty liver disease (NAFLD). , 2012, Journal of hepatology.

[102]  A. Kahraman,et al.  Liver Transplantation in Nonalcoholic Steatohepatitis Is Associated with High Mortality and Post-Transplant Complications: A Single-Center Experience , 2012, Digestion.

[103]  N. Johnson,et al.  Exercise and non-alcoholic fatty liver disease: a systematic review and meta-analysis. , 2012, Journal of hepatology.

[104]  N. Chalasani,et al.  What Should We Recommend to Our Patients with NAFLD Regarding Alcohol Use? , 2012, The American Journal of Gastroenterology.

[105]  K. Watson,et al.  Effect of regression from prediabetes to normal glucose regulation on long-term reduction in diabetes risk: results from the Diabetes Prevention Program Outcomes Study , 2012, The Lancet.

[106]  K. Cusi,et al.  The Diagnosis and Management of Non-alcoholic Fatty Liver Disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association , 2012, The American Journal of Gastroenterology.

[107]  V. Wong,et al.  Non-invasive diagnosis of non-alcoholic steatohepatitis by combined serum biomarkers. , 2012, Journal of hepatology.

[108]  Christopher D Byrne,et al.  Non-alcoholic fatty liver disease: a new and important cardiovascular risk factor? , 2012, European heart journal.

[109]  P. Vajro,et al.  Diagnosis of Nonalcoholic Fatty Liver Disease in Children and Adolescents: Position Paper of the ESPGHAN Hepatology Committee , 2012, Journal of pediatric gastroenterology and nutrition.

[110]  Zhi‐Jie Zheng,et al.  Metformin for liver cancer prevention in patients with type 2 diabetes: a systematic review and meta-analysis. , 2012, The Journal of clinical endocrinology and metabolism.

[111]  D. Samuel,et al.  Twenty-year protocol liver biopsies: Invasive but useful for the management of liver recipients. , 2012, Journal of hepatology.

[112]  Catriona A. Burdon,et al.  Omega-3 supplementation and non-alcoholic fatty liver disease: a systematic review and meta-analysis. , 2012, Journal of hepatology.

[113]  Kwok-Kin Wong,et al.  Metformin Prevents Liver Tumorigenesis by Inhibiting Pathways Driving Hepatic Lipogenesis , 2012, Cancer Prevention Research.

[114]  K. Clément,et al.  Performance of Biomarkers FibroTest, ActiTest, SteatoTest, and NashTest in Patients with Severe Obesity: Meta Analysis of Individual Patient Data , 2012, PloS one.

[115]  J. Hardies,et al.  Prevalence of Prediabetes and Diabetes and Metabolic Profile of Patients With Nonalcoholic Fatty Liver Disease (NAFLD) , 2012, Diabetes Care.

[116]  A. Tura,et al.  Fatty Liver Index Predicts Further Metabolic Deteriorations in Women with Previous Gestational Diabetes , 2012, PloS one.

[117]  G. Frühbeck,et al.  Body mass index classification misses subjects with increased cardiometabolic risk factors related to elevated adiposity , 2012, International Journal of Obesity.

[118]  Yoshiyuki Suzuki,et al.  Large-Scale Long-Term Follow-Up Study of Japanese Patients With Non-Alcoholic Fatty Liver Disease for the Onset of Hepatocellular Carcinoma , 2012, The American Journal of Gastroenterology.

[119]  D. Kleiner,et al.  Nonalcoholic Fatty Liver Disease: Pathologic Patterns and Biopsy Evaluation in Clinical Research , 2012, Seminars in Liver Disease.

[120]  M. Christensen,et al.  Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials , 2012, BMJ : British Medical Journal.

[121]  C. Lawton,et al.  Vitamin E and the Risk of Prostate Cancer: The Selenium and Vitamin E Cancer Prevention Trial (SELECT) , 2012 .

[122]  Christian Thoma,et al.  Lifestyle interventions for the treatment of non-alcoholic fatty liver disease in adults: a systematic review. , 2012, Journal of hepatology.

[123]  K. Clément,et al.  Chronic intermittent hypoxia is a major trigger for non-alcoholic fatty liver disease in morbid obese. , 2012, Journal of hepatology.

[124]  A. Feldstein,et al.  Pentoxifylline improves nonalcoholic steatohepatitis: A randomized placebo‐controlled trial , 2011, Hepatology.

[125]  J. Heimbach,et al.  Frequency and outcomes of liver transplantation for nonalcoholic steatohepatitis in the United States. , 2011, Gastroenterology.

[126]  M. Bulsara,et al.  Complex non‐invasive fibrosis models are more accurate than simple models in non‐alcoholic fatty liver disease , 2011, Journal of gastroenterology and hepatology.

[127]  Shira Zelber-Sagi,et al.  Nutrition and physical activity in NAFLD: an overview of the epidemiological evidence. , 2011, World journal of gastroenterology.

[128]  W. Rathmann,et al.  Association between Markers of Fatty Liver Disease and Impaired Glucose Regulation in Men and Women from the General Population: The KORA-F4-Study , 2011, PloS one.

[129]  A. Baranova,et al.  Systematic review: the epidemiology and natural history of non‐alcoholic fatty liver disease and non‐alcoholic steatohepatitis in adults , 2011, Alimentary pharmacology & therapeutics.

[130]  Paolo Crosignani,et al.  Fatty liver index and mortality: The cremona study in the 15th year of follow‐up , 2011, Hepatology.

[131]  F. Pattou,et al.  Validation of noninvasive biomarkers (FibroTest, SteatoTest, and NashTest) for prediction of liver injury in patients with morbid obesity , 2011, European journal of gastroenterology & hepatology.

[132]  V. Wong,et al.  Coronary artery disease and cardiovascular outcomes in patients with non-alcoholic fatty liver disease , 2011, Gut.

[133]  T. Saibara,et al.  Characteristics of patients with nonalcoholic steatohepatitis who develop hepatocellular carcinoma. , 2011, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[134]  P. Rosenthal,et al.  Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial. , 2011, JAMA.

[135]  B. Neuschwander‐Tetri,et al.  Nonalcoholic fatty liver disease (NAFLD) activity score and the histopathologic diagnosis in NAFLD: distinct clinicopathologic meanings , 2011, Hepatology.

[136]  T. Saibara,et al.  A simple clinical scoring system using ferritin, fasting insulin, and type IV collagen 7S for predicting steatohepatitis in nonalcoholic fatty liver disease , 2011, Journal of Gastroenterology.

[137]  Christophe Tzourio,et al.  Effects of vitamin E on stroke subtypes: meta-analysis of randomised controlled trials , 2010, BMJ : British Medical Journal.

[138]  F. Berthier,et al.  A new composite model including metabolic syndrome, alanine aminotransferase and cytokeratin‐18 for the diagnosis of non‐alcoholic steatohepatitis in morbidly obese patients , 2010, Alimentary pharmacology & therapeutics.

[139]  A. Alisi,et al.  I148M patatin‐like phospholipase domain‐containing 3 gene variant and severity of pediatric nonalcoholic fatty liver disease , 2010, Hepatology.

[140]  Enzo Bonora,et al.  Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. , 2010, The New England journal of medicine.

[141]  N. Sattar,et al.  Liver enzymes, nonalcoholic fatty liver disease, and incident cardiovascular disease: A narrative review and clinical perspective of prospective data , 2010, Hepatology.

[142]  A. Burt,et al.  Simple non-invasive fibrosis scoring systems can reliably exclude advanced fibrosis in patients with non-alcoholic fatty liver disease , 2022 .

[143]  G. Bedogni,et al.  A simple index of lipid overaccumulation is a good marker of liver steatosis , 2010, BMC gastroenterology.

[144]  Kunihiro Hosono,et al.  Nonalcoholic fatty liver disease: US-based acoustic radiation force impulse elastography. , 2010, Radiology.

[145]  Chris Day,et al.  A position statement on NAFLD/NASH based on the EASL 2009 special conference. , 2010, Journal of hepatology.

[146]  T. Berg,et al.  High‐dose ursodeoxycholic acid therapy for nonalcoholic steatohepatitis: a double‐blind, randomized, placebo‐controlled trial , 2010, Hepatology.

[147]  J. Stoker,et al.  The diagnostic accuracy of US, CT, MRI and 1H-MRS for the evaluation of hepatic steatosis compared with liver biopsy: a meta-analysis , 2010, European Radiology.

[148]  D. Reboussin,et al.  Effect of a 12-Month Intensive Lifestyle Intervention on Hepatic Steatosis in Adults With Type 2 Diabetes , 2010, Diabetes Care.

[149]  H. Kim,et al.  Hepatic steatosis index: a simple screening tool reflecting nonalcoholic fatty liver disease. , 2010, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[150]  Beverley Balkau,et al.  articleNine-year incident diabetes is predicted by fatty liver indices : the French D . E . S . I . R . study , 2015 .

[151]  Rocio Lopez,et al.  The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis , 2010, Hepatology.

[152]  B. Neuschwander‐Tetri,et al.  Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. , 2010, The New England journal of medicine.

[153]  G. Lippi,et al.  Non-alcoholic fatty liver disease is independently associated with an increased prevalence of chronic kidney disease and retinopathy in type 1 diabetic patients , 2010, Diabetologia.

[154]  E. Bugianesi,et al.  Homozygosity for the patatin‐like phospholipase‐3/adiponutrin I148M polymorphism influences liver fibrosis in patients with nonalcoholic fatty liver disease , 2010, Hepatology.

[155]  A. Ananthakrishnan,et al.  A Noninvasive Clinical Scoring Model Predicts Risk of Nonalcoholic Steatohepatitis in Morbidly Obese Patients , 2010, Obesity surgery.

[156]  V. de Lédinghen,et al.  Pitfalls of liver stiffness measurement: A 5‐year prospective study of 13,369 examinations , 2010, Hepatology.

[157]  P. Giral,et al.  Long‐term efficacy of rosiglitazone in nonalcoholic steatohepatitis: Results of the fatty liver improvement by rosiglitazone therapy (FLIRT 2) extension trial , 2009, Hepatology.

[158]  Greger Lindberg,et al.  Decreased survival of subjects with elevated liver function tests during a 28‐year follow‐up , 2010, Hepatology.

[159]  Julien Vergniol,et al.  Diagnosis of fibrosis and cirrhosis using liver stiffness measurement in nonalcoholic fatty liver disease , 2010, Hepatology.

[160]  E. Jackvony,et al.  Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis , 2010, Hepatology.

[161]  J. Newton,et al.  Potential strategies to improve uptake of exercise interventions in non-alcoholic fatty liver disease. , 2010, Journal of hepatology.

[162]  M. Raponi,et al.  Pediatric non-alcoholic fatty liver disease: preventive and therapeutic value of lifestyle intervention. , 2009, World journal of gastroenterology.

[163]  A. Sanyal,et al.  Comparison of noninvasive markers of fibrosis in patients with nonalcoholic fatty liver disease. , 2009, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[164]  N. Lundbom,et al.  Prediction of non-alcoholic fatty liver disease and liver fat using metabolic and genetic factors. , 2009, Gastroenterology.

[165]  J. Benson,et al.  The natural history of non-alcoholic fatty liver disease , 2006 .

[166]  Beverley Balkau,et al.  Fatty liver is associated with insulin resistance, risk of coronary heart disease, and early atherosclerosis in a large European population , 2009, Hepatology.

[167]  Gustavo Castaño,et al.  A diagnostic model to differentiate simple steatosis from nonalcoholic steatohepatitis based on the likelihood ratio form of Bayes theorem. , 2009, Clinical biochemistry.

[168]  W. Coyle,et al.  The effect of metformin and standard therapy versus standard therapy alone in nondiabetic patients with insulin resistance and nonalcoholic steatohepatitis (NASH): a pilot trial , 2009, Therapeutic advances in gastroenterology.

[169]  B. Neuschwander‐Tetri,et al.  Portal chronic inflammation in nonalcoholic fatty liver disease (NAFLD): A histologic marker of advanced NAFLD—Clinicopathologic correlations from the nonalcoholic steatohepatitis clinical research network , 2009, Hepatology.

[170]  K. Birkeland,et al.  Metformin in patients with non-alcoholic fatty liver disease: A randomized, controlled trial , 2009, Scandinavian journal of gastroenterology.

[171]  B. Neuschwander‐Tetri,et al.  Orlistat for overweight subjects with nonalcoholic steatohepatitis: A randomized, prospective trial , 2009, Hepatology.

[172]  M. Simrén.  High- or Low-Carbohydrate Diets: Which Is Better for Weight Loss, Insulin Resistance, and Fatty Livers? , 2009 .

[173]  F. Laine,et al.  Comparison of blood tests for liver fibrosis specific or not to NAFLD. , 2009, Journal of hepatology.

[174]  M. Taniai,et al.  Hepatocellular carcinoma in patients with nonalcoholic steatohepatitis , 2009, Journal of Gastroenterology.

[175]  Z. Halpern,et al.  Role of leisure‐time physical activity in nonalcoholic fatty liver disease: A population‐based study , 2008, Hepatology.

[176]  G. Aithal,et al.  Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis. , 2008, Gastroenterology.

[177]  Alexander Pertsemlidis,et al.  Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease , 2008, Nature Genetics.

[178]  Philippe Giral,et al.  Rosiglitazone for nonalcoholic steatohepatitis: one-year results of the randomized placebo-controlled Fatty Liver Improvement with Rosiglitazone Therapy (FLIRT) Trial. , 2008, Gastroenterology.

[179]  G. Lippi,et al.  NASH Predicts Plasma Inflammatory Biomarkers Independently of Visceral Fat in Men , 2008, Obesity.

[180]  E. Vittinghoff,et al.  A clinical scoring system for predicting nonalcoholic steatohepatitis in morbidly obese patients , 2008, Hepatology.

[181]  A. Baranova,et al.  A Novel Diagnostic Biomarker Panel for Obesity-related Nonalcoholic Steatohepatitis (NASH) , 2008, Obesity surgery.

[182]  G. Guyatt,et al.  GRADE: an emerging consensus on rating quality of evidence and strength of recommendations , 2008, BMJ : British Medical Journal.

[183]  B. Neuschwander‐Tetri,et al.  Development and validation of a simple NAFLD clinical scoring system for identifying patients without advanced disease , 2008, Gut.

[184]  I. Guha,et al.  Noninvasive markers of fibrosis in nonalcoholic fatty liver disease: Validating the European Liver Fibrosis Panel and exploring simple markers , 2007, Hepatology.

[185]  P. Scifo,et al.  Increased mediastinal fat and impaired left ventricular energy metabolism in young men with newly found fatty liver , 2007, Hepatology.

[186]  A. Hakkarainen,et al.  Liver fat is increased in type 2 diabetic patients and underestimated by serum alanine aminotransferase compared with equally obese nondiabetic subjects. , 2008 .

[187]  L. N. Valenti,et al.  Carotid artery intima-media thickness in nonalcoholic fatty liver disease. , 2008, The American journal of medicine.

[188]  Yuichi Harano,et al.  The Severity of Ultrasonographic Findings in Nonalcoholic Fatty Liver Disease Reflects the Metabolic Syndrome and Visceral Fat Accumulation , 2007, The American Journal of Gastroenterology.

[189]  Ross J. Harris,et al.  Gamma-Glutamyltransferase Is Associated With Incident Vascular Events Independently of Alcohol Intake: Analysis of the British Women’s Heart and Health Study and Meta-Analysis , 2007, Arteriosclerosis, thrombosis, and vascular biology.

[190]  Amalia Gastaldelli,et al.  Relationship between hepatic/visceral fat and hepatic insulin resistance in nondiabetic and type 2 diabetic subjects. , 2007, Gastroenterology.

[191]  L. N. Valenti,et al.  Iron Depletion by Phlebotomy Improves Insulin Resistance in Patients With Nonalcoholic Fatty Liver Disease and Hyperferritinemia: Evidence from a Case-Control Study , 2007, The American Journal of Gastroenterology.

[192]  T. Therneau,et al.  The NAFLD fibrosis score: A noninvasive system that identifies liver fibrosis in patients with NAFLD , 2007, Hepatology.

[193]  A. Häkkinen,et al.  Effects of insulin therapy on liver fat content and hepatic insulin sensitivity in patients with type 2 diabetes. , 2007, American journal of physiology. Endocrinology and metabolism.

[194]  Christian Gluud,et al.  Mortality in randomized trials of antioxidant supplements for primary and secondary prevention: systematic review and meta-analysis. , 2007, JAMA.

[195]  G. Makar.  A Placebo-Controlled Trial of Pioglitazone in Subjects with Nonalcoholic Steatohepatitis , 2007 .

[196]  J. Dufour,et al.  Randomized placebo-controlled trial of ursodeoxycholic acid with vitamin e in nonalcoholic steatohepatitis. , 2006, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[197]  J. Hardies,et al.  A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. , 2006, The New England journal of medicine.

[198]  Dominique Thabut,et al.  Diagnostic value of biochemical markers (NashTest) for the prediction of non alcoholo steato hepatitis in patients with non-alcoholic fatty liver disease , 2006, BMC gastroenterology.

[199]  Anna Castiglione,et al.  The Fatty Liver Index: a simple and accurate predictor of hepatic steatosis in the general population , 2006, BMC gastroenterology.

[200]  M. Holmqvist,et al.  Long‐term follow‐up of patients with NAFLD and elevated liver enzymes , 2006, Hepatology.

[201]  G. Targher,et al.  Increased prevalence of cardiovascular disease in Type 2 diabetic patients with non‐alcoholic fatty liver disease , 2006, Diabetic medicine : a journal of the British Diabetic Association.

[202]  V. de Lédinghen,et al.  Diagnostic value of biochemical markers (FibroTest-FibroSURE) for the prediction of liver fibrosis in patients with non-alcoholic fatty liver disease , 2006, BMC gastroenterology.

[203]  T. Lehtimäki,et al.  Liver steatosis coexists with myocardial insulin resistance and coronary dysfunction in patients with type 2 diabetes. , 2006, American journal of physiology. Endocrinology and metabolism.

[204]  H. Kahn.  The lipid accumulation product is better than BMI for identifying diabetes: a population-based comparison. , 2006, Diabetes care.

[205]  F. Oberti,et al.  A novel panel of blood markers to assess the degree of liver fibrosis , 2005, Hepatology.

[206]  A. Alberti,et al.  Review article: chronic hepatitis C – natural history and cofactors , 2005, Alimentary pharmacology & therapeutics.

[207]  J. Kench,et al.  Hepascore: an accurate validated predictor of liver fibrosis in chronic hepatitis C infection. , 2005, Clinical chemistry.

[208]  H. Kahn,et al.  The "lipid accumulation product" performs better than the body mass index for recognizing cardiovascular risk: a population-based comparison , 2005, BMC cardiovascular disorders.

[209]  C. Nievergelt,et al.  Histopathology of pediatric nonalcoholic fatty liver disease , 2005, Hepatology.

[210]  H. Lo,et al.  Sonographic fatty liver, overweight and ischemic heart disease. , 2005, World journal of gastroenterology.

[211]  Mark Fishbein,et al.  Hepatic MRI for Fat Quantitation: Its Relationship to Fat Morphology, Diagnosis, and Ultrasound , 2005, Journal of clinical gastroenterology.

[212]  G. Marchesini,et al.  Endothelial dysfunction and cardiovascular risk profile in nonalcoholic fatty liver disease , 2005, Hepatology.

[213]  G. Bedogni,et al.  Prevalence of and risk factors for nonalcoholic fatty liver disease: The Dionysos nutrition and liver study , 2005, Hepatology.

[214]  P. Giral,et al.  Sampling variability of liver biopsy in nonalcoholic fatty liver disease. , 2005, Gastroenterology.

[215]  O. Cummings,et al.  Design and validation of a histological scoring system for nonalcoholic fatty liver disease , 2005, Hepatology.

[216]  G. Marchesini,et al.  A Randomized Controlled Trial of Metformin versus Vitamin E or Prescriptive Diet in Nonalcoholic Fatty Liver Disease , 2005, The American Journal of Gastroenterology.

[217]  Emilio Ros,et al.  Nonalcoholic Fatty Liver Disease Is Associated With Carotid Atherosclerosis: A Case–Control Study , 2005, Arteriosclerosis, thrombosis, and vascular biology.

[218]  K. Petersen,et al.  Reversal of nonalcoholic hepatic steatosis, hepatic insulin resistance, and hyperglycemia by moderate weight reduction in patients with type 2 diabetes. , 2005, Diabetes.

[219]  S. Sanderson,et al.  The histological course of nonalcoholic fatty liver disease: a longitudinal study of 103 patients with sequential liver biopsies. , 2005, Journal of hepatology.

[220]  Y. Jang,et al.  Standards of Medical Care in Diabetes-2010 by the American Diabetes Association: Prevention and Management of Cardiovascular Disease , 2010 .

[221]  G. Zoppini,et al.  Relation of nonalcoholic hepatic steatosis to early carotid atherosclerosis in healthy men: role of visceral fat accumulation. , 2004, Diabetes care.

[222]  A. Häkkinen,et al.  Effects of rosiglitazone and metformin on liver fat content, hepatic insulin resistance, insulin clearance, and gene expression in adipose tissue in patients with type 2 diabetes. , 2004, Diabetes.

[223]  S. Caldwell,et al.  The spectrum expanded: cryptogenic cirrhosis and the natural history of non-alcoholic fatty liver disease. , 2004, Journal of hepatology.

[224]  L. Burgart,et al.  Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: Results of a randomized trial , 2004, Hepatology.

[225]  E. Abdalla,et al.  Obesity and diabetes as a risk factor for hepatocellular carcinoma , 2004, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[226]  R. Groszmann,et al.  American association for the study of liver diseases , 1992 .

[227]  R. Turner,et al.  Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man , 1985, Diabetologia.

[228]  J. Kalbfleisch,et al.  A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C , 2003, Hepatology.

[229]  L. Balart,et al.  Problems with NASH? HAIR is some help: Dixon JB, Bhathal PS, O’Brien PE, Nonalcoholic Fatty Liver Disease: Predictors of Nonalcoholic Steatohepatitis and Liver Fibrosis in the Severely Obese, Gastroenterology 2001;121:91–100 , 2003 .

[230]  C. Ryan,et al.  One hundred consecutive hepatic biopsies in the workup of living donors for right lobe liver transplantation , 2002, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[231]  J. Marrero,et al.  NAFLD may be a common underlying liver disease in patients with hepatocellular Carcinoma in the United States , 2002, Hepatology.

[232]  M. Roden,et al.  Effects of insulin treatment in type 2 diabetic patients on intracellular lipid content in liver and skeletal muscle. , 2002, Diabetes.

[233]  Erick M Remer,et al.  The utility of radiological imaging in nonalcoholic fatty liver disease. , 2002, Gastroenterology.

[234]  Mauro Salizzoni,et al.  Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma. , 2002, Gastroenterology.

[235]  J. Dixon,et al.  Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese. , 2001, Gastroenterology.

[236]  G. Brandi,et al.  Prevalence of and Risk Factors for Hepatic Steatosis in Northern Italy , 2000, Annals of Internal Medicine.